UR7516 "CHIMERE, Université de Picardie Jules Verne", Amiens, France.
Centre de Biologie Humaine, CHU Amiens, Amiens, France.
Ann Surg Oncol. 2021 Oct;28(11):5842-5854. doi: 10.1245/s10434-021-09904-0. Epub 2021 Apr 12.
Oral squamous cell carcinoma (OSCC) is the most frequent type of tumor arising from the oral cavity. Surgery is the cornerstone of the treatment of these cancers. Tumor biology has long been overlooked as an important contributor to the outcome of surgical procedures, but recent studies are challenging this concept. Molecular analyses of tumor DNA or RNA provide a rich source of information about the biology of OSCC.
We searched for relevant articles using PubMed. We examined in particular the prospect of applying molecular methods for minimally invasive exploration of OSCC biology.
We examined five potential applications of genomics to the surgical management and study of OSCC: i) assessing oral potentially malignant lesions; ii) tumor staging prior to surgery; iii) predicting postoperative risk in locally advanced tumors; iv) measuring minimal residual disease and optimizing the longitudinal monitoring of OSCC; and v) predicting the efficacy of medical treatment.
Genomic information can be harnessed in order to identify new biomarkers that could improve the staging, choice of therapy and management of OSCC. The identification of new biomarkers is awaited for better personalization of the surgical treatment of OSCC.
口腔鳞状细胞癌（OSCC）是口腔最常见的肿瘤类型。手术是这些癌症治疗的基石。肿瘤生物学长期以来被忽视，被认为是手术结果的一个重要因素，但最近的研究对这一概念提出了挑战。对肿瘤 DNA 或 RNA 的分子分析为 OSCC 生物学提供了丰富的信息来源。
我们使用 PubMed 搜索了相关文章。我们特别研究了应用分子方法微创探索 OSCC 生物学的前景。
我们检查了基因组学在口腔鳞状细胞癌外科治疗和研究中的五个潜在应用：i）评估口腔潜在恶性病变；ii）手术前肿瘤分期；iii）预测局部晚期肿瘤的术后风险；iv）测量微小残留疾病和优化 OSCC 的纵向监测；v）预测药物治疗的效果。
可以利用基因组信息来识别新的生物标志物，从而改善 OSCC 的分期、治疗选择和管理。新的生物标志物的鉴定有望更好地实现 OSCC 手术治疗的个体化。
